Transforming growth factor-β-induced miR-143 expression in regulation of non-small cell lung cancer cell viability and invasion capacity in vitro and in vivo

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1977-1988

  Cheng, Tianli ^a   Hu, Chengping ^a   Yang, Huaping ^a   Cao, Liming ^a   An, Jian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

MiR 143; MiRNA; NSCLC; TGF

Indexed keywords

HERMES ANTIGEN; K RAS PROTEIN; MICRORNA 143; MICRORNA 145; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; MICRORNA;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LUNG CAPACITY; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WOUND HEALING; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907219376     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2623     Document Type: Article

References (37)

1. Field JK, Oudkerk M, Pedersen JH and Duffy SW: Prospects for population screening and diagnosis of lung cancer. Lancet 382: 732-741, 2013.
2. Curioni-Fontecedro A, Husmann L, Soldini D and Stahel RA: Primary non-small cell lung cancer response upon treatment with denosumab. Lung Cancer 82: 506-508, 2013.
3. Navarro A, Diaz T, Gallardo E, et al: Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol 103: 411-415, 2011.
4. Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A and Annilo T: Meta-Analysis of microRNA expression in lung cancer. Int J Cancer 132: 2884-2893, 2013.
5. Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell 153: 516-519, 2013.
6. Chitwood DH and Timmermans MC: Small RNAs are on the move. Nature 467: 415-419, 2010.
7. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
8. Ebert MS and Sharp PA: Roles for microRNAs in conferring robustness to biological processes. Cell 149: 515-524, 2012.
9. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
10. Bowen T, Jenkins RH and Fraser DJ: MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol 229: 274-285, 2013.
11. Luo Z, Dai Y, Zhang L, et al: MiR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis 34: 415-425, 2013.
12. Liu L, Yu X, Guo X, et al: MiR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep 5: 753-760, 2012.
13. Yoshida K, Saito T, Kamida A, et al: Transforming growth factor-beta transiently induces vimentin expression and invasive capacity in a canine mammary gland tumor cell line. Res Vet Sci 94: 539-541, 2013.
14. Dong L, Ge XY, Wang YX, et al: Transforming growth factorbeta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 49: 1051-1058 2013.
15. Tian M, Neil JR and Schiemann WP: Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 23: 951-962, 2011.
16. Choe C, Shin YS, Kim SH, et al: Tumor-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway. Anticancer Res 33: 3715-3723, 2013.
17. Huang S, Holzel M, Knijnenburg T, et al: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151: 937-950, 2012.
18. Argast GM, Krueger JS, Thomson S, et al: Inducible expression of TGFbeta, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis 28: 593-614, 2011.
19. Tai J, Xiao X, Huang ZG, et al: MicroRNAs regulate epithelialmesenchymal transition of supraglottic laryngeal cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48: 499-503, 2013 (In Chinese).
20. Peng X, Guo W, Liu T, et al: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6: E20341, 2011.
21. Boominathan L: The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One 5: E10615, 2010.
22. Davis-Dusenbery BN, Chan MC, Reno KE, et al: Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem 286: 28097-28110, 2011.
23. Wang YY, Ren T, Cai YY and He XY: MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm 28: 131-137, 2013.
24. Shi L, Campbell G, Jones WD, et al: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28: 827-838, 2010.
25. Gordon KJ and Blobe GC: Role of transforming growth factorbeta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782: 197-228, 2008.
26. Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358, 2000.
27. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
28. Gao W, Yu Y, Cao H, et al: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 64: 399-408, 2010.
29. Ma Q, Jiang Q, Pu Q, et al: MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci 9: 680-692, 2013.
30. Hu Y, Ou Y, Wu K, Chen Y and Sun W: MiR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol 33: 1863-1870, 2012.
31. Liu H, Zhang SZ, Cai SR, Peng JP and Zheng S: Effect of microRNA143 expression on cell proliferation in colonic carcinoma. Zhonghua Zhong Liu Za Zhi 30: 498-501, 2008 (In Chinese).
32. Tabyaoui I, Tahiri-Jouti N, Serhier Z, et al: Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data. Diagn Pathol 8: 39, 2013.
33. Hiraga T, Ito S and Nakamura H: Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 73: 4112-4122, 2013.
34. Raso-Barnett L, Banky B, Barbai T, Becsagh P, Timar J and Raso E: Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression. PLoS One 8: E53883, 2013.
35. Zeller E, Hammer K, Kirschnick M and Braeuning A: Mechanisms of RAS/beta-catenin interactions. Arch Toxicol 87: 611-632, 2013.
36. Sawaki D and Suzuki T: Targeting transforming growth factorbeta signaling in aortopathies in Marfan syndrome. Circ J 77: 898-899, 2013.
37. Jakobsson L and van Meeteren LA: Transforming growth factor beta family members in regulation of vascular function: In the light of vascular conditional knockouts. Exp Cell Res 319: 1264-1270, 2013.